Answers are grounded in this paper and cite their sources.
Inflammation contributes significantly to poor outcomes after acute brain injury (ABI), but it remains unclear which inflammatory biomarkers best reflect this process in intensive care unit (ICU) patients. This review summarizes current findings on interleukins (IL) and their timing post-ABI to guide future monitoring and research. We searched PubMed, Scopus, and Web of Science for studies examining interleukin biomarkers in non-infectious ABI populations admitted to the ICU, focusing on peer-reviewed human studies linking inflammatory markers to injury severity, pathophysiology, or neurologic outcomes. Included studies predominantly involved patients with traumatic brain injury (TBI), subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), and mixed ABI populations, and examined interleukin-mediated inflammatory responses across cerebrospinal fluid (CSF), interstitial fluid (ISF), and blood compartments. Interleukin-6 (IL-6), higher in CSF than plasma after ABI, is consistent with local neuroinflammation and correlates with severity and outcomes. IL-8 shows variable changes—often higher in severe TBI with worse outcomes but sometimes suppressed early in serum—reflecting dynamic, context-dependent inflammation. IL-10 displays sustained elevations associated with poor outcomes in several cohorts. IL-1β peaks in the brain by day 2 (notably in SAH), with early systemic surges normalizing over weeks; higher serum levels were associated with reduced heart rate variability on day 1 and unfavorable outcomes on day 3. In TBI, IL-2 and IL-4 show non-significant differences in febrile compared to non-febrile patients, IL-13 rises with greater severity and relates to Glasgow Coma Scale (GCS), and IL-18 distinguishes patients from controls but not by severity. Interleukins are potentially informative biomarkers in the ABI population and particularly TBI, although none has been externally validated for clinical use. IL-6, the most studied interleukin, correlates with acute and long-term recovery.
No takes yet. Share an insight, caveat, or question.
Darvishi‐Khezri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: